A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N
Sundquist, Fredrik; Georgantzi, Kleopatra; Jarvis, Kirsten Brunsvig; Brok, Jesper; Koskenvuo, Minna; Rascon, Jelena; van Noesel, Max; Grybäck, Per; Nilsson, Joachim; Braat, Arthur; Sundin, Mikael; Wessman, Sandra; Herold, Nikolas; Hjorth, Lars; Kogner, Per; Granberg, Dan; Gaze, Mark; Stenman, Jakob
(2022) Frontiers in Pediatrics, volume 10, pp. 1 - 11
(Article)
Abstract
Background: Half the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor. 131I-mIBG is the most widely used form in current use, but is not universally effective. Clinical trials of 177Lutetium DOTATATE have so far had disappointing results, possibly
... read more
because the administered activity was too low, and the courses were spread over too long a period of time, for a rapidly proliferating tumor. We have devised an alternative administration schedule to overcome these limitations. This involves two high-activity administrations of single agent 177Lu-DOTATATE given 2 weeks apart, prescribed as a personalized whole body radiation absorbed dose, rather than a fixed administered activity. "A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma - LuDO-N" (EudraCT No: 2020-004445-36, ClinicalTrials.gov Identifier: NCT04903899) evaluates this new dosing schedule. Methods: The LuDO-N trial is a phase II, open label, multi-center, single arm, two stage design clinical trial. Children aged 18 months to 18 years are eligible. The trial is conducted by the Nordic Society for Pediatric Hematology and Oncology (NOPHO) and it has been endorsed by SIOPEN (https://www.siopen.net). The Karolinska University Hospital, is the sponsor of the LuDO-N trial, which is conducted in collaboration with Advanced Accelerator Applications, a Novartis company. All Scandinavian countries, Lithuania and the Netherlands participate in the trial and the UK has voiced an interest in joining in 2022. Results: The pediatric use of the Investigational Medicinal Product (IMP) 177Lu-DOTATATE, as well as non-IMPs SomaKit TOC® (68Ga-DOTATOC) and LysaKare® amino acid solution for renal protection, have been approved for pediatric use, within the LuDO-N Trial by the European Medicines Agency (EMA). The trial is currently recruiting. Recruitment is estimated to be finalized within 3-5 years. Discussion: In this paper we present the protocol of the LuDO-N Trial. The rationale and design of the trial are discussed in relation to other ongoing, or planned trials with similar objectives. Further, we discuss the rapid development of targeted radiopharmaceutical therapy and the future perspectives for developing novel therapies for high-risk neuroblastoma and other pediatric solid tumors.
show less
Download/Full Text
Keywords: Lu-DOTATATE, high-risk, neuroblastoma, PRRT, radiopharmaceutical, refractory, relapse, therapy, Pediatrics, Perinatology, and Child Health, Journal Article
ISSN: 2296-2360
Publisher: Frontiers Media S. A.
Note: Funding Information: This study received funding from Applied Accelerator Applications, a Novartis company. The funder had the following involvement with the study: Advice on trial design, provision of all investigational and non-investigational products, free of charge for the LuDO-N trial and review of the final manuscript. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding Information: We are deeply thankful to Sanna Nystr?m and Claudia Maes at the Center for Clinical Cancer Studies at the Karolinska University Hospital for providing expert assistance in generating the eCRF and in administrative management of the trial, as well as to Helena Aar?e, Pernilla Callerstr?m, Rut-Inger Enryd and Sofie Garpemo at the pediatric clinical trial unit HOPE at the Karolinska University Hospital, for providing expert assistance in the setup and clinical management of the trial, and finally to Daniela Niepel at Advanced Accelerator Applications / Novartis for valuable feedback on the manuscript. Funding Information: The LuDO-N trial has been supported by funding from the Swedish Cancer Society, the Swedish Childhood Cancer Fund, Region Stockholm and Applied Accelerator Applications / Novartis. In addition, all investigational and non-investigational products have been provided free of charge for the LuDO-N trial by Applied Accelerator Applications / Novartis. MG was supported by the National Institute for Health Research, University College London Hospitals, Biomedical Research Center and the Radiation Research Unit at the Cancer Research UK City of London Center Award (C7893/A28990). Publisher Copyright: Copyright © 2022 Sundquist, Georgantzi, Jarvis, Brok, Koskenvuo, Rascon, van Noesel, Grybäck, Nilsson, Braat, Sundin, Wessman, Herold, Hjorth, Kogner, Granberg, Gaze and Stenman.
(Peer reviewed)
